Stocks to Sell

Stocks can plunge for any number of reasons — investors may need to raise cash for large milestone purchases, or algorithms could be triggered by stop losses which create massive selloffs. Whatever the case, InvestorPlace’s journalists weed out the markets’ losers, keeping you informed of which stocks to cash out of before they come crashing down.

Ford Stock Isn’t Quite at the End of Its Road, But It Won’t Run Forever

By Dana Blankenhorn, InvestorPlace Contributor
Ford is well-positioned in the electric vehicle race. But Electric cars don't have to be repaired and replaced like gas-powered vehicles.

Lucid Stock Makes Tesla Look Cheap

By Dana Blankenhorn, InvestorPlace Contributor
LCID stock has a ridiculously high valuation, especially given that the future of transportation could be very different.

Take Some Profits After IonQ’s Q3 Earnings Report

By Ian Bezek, InvestorPlace Contributor
IONQ stock looks overvalued following a mixed earnings report. Expect ups and downs in the name, as quantum computing won't go mainstream overnight.

Sell QuantumScape Stock After Recent Rally

By Ian Bezek, InvestorPlace Contributor
This looks like a good profit-taking opportunity in QS stock. While shares are up strongly, the fundamental outlook for the company remains mixed.

7 Stocks to Sell Before the ‘Great Resignation’ Hits Their Bottom Line

By Ian Bezek, InvestorPlace Contributor
Workers are quitting their jobs at record rates, and labor strikes are back in fashion. Here are stocks vulnerable to the Great Resignation.

Exela Stock Is an Incredibly Risky Play With Limited Upside

By Muslim Farooque, InvestorPlace Contributor
Exela has a massive debt load and is unable to grow its sales to push towards profitability. Best to avoid XELA stock for now.

Lucid Stock Needs a Sharp Correction to Become an Attractive EV Play

By Faizan Farooque, InvestorPlace Contributor
LCID stock is doing exceptionally well, but like most EV companies out there but don't count your chickens before they hatch.

ContextLogic Stock Suffers as Platform Loses Users to Pandemic Aftermath

By Faizan Farooque, InvestorPlace Contributor
Chances for a turnaround for WISH stock are slim as product quality issues, declining users and sluggish revenue growth weigh it down.

DiDi Is Surrounded by Too Much Uncertainty

By Joel Baglole, InvestorPlace Contributor
Chinese ride hailing company DiDi continues to operate under a cloud of uncertainty as regulators loom. Avoid DIDI stock for now.

How Elon Musk Got It Right About Rivian and Its Irrational Valuation

By Stavros Georgiadis, CFA, InvestorPlace Contributor
Rivian seems like another hot EV name with extremely lofty expectations. RIVN stock has an elevated price as well as an irrational valuation.

The Turnaround of IBM Stock Has Yet To Begin

By Joel Baglole, InvestorPlace Contributor
IBM recently split into two publicly traded companies, but even that major milestone has not been enough to turn around its share price.

Rivian Can Barely Sell Trucks Fast Enough for Its High Stock Price

By Mark R. Hake, CFA
Rivian plans on selling a lot of its electric trucks, but not so many that you should buy RIVN stock at its elevated price.

Blackberry Is a Pricey IoT Wager With Uncertain Payoff Potential

By Thomas Niel, InvestorPlace Contributor
The issue? Still sporting meme stock status, there's no discount, despite the uncertainty. With this, side with the bears for now with BB stock.

Avoid SmileDirectClub Stock as CEO Plays the Blame Game

By David Moadel, InvestorPlace Contributor
As SDC stock enters into a bear market, investors should demand accountability and expect better fiscal performance from the company.

Follow the CEO’s Example and Sell Your AMC Stock

By Will Ashworth, InvestorPlace Contributor
AMC CEO Adam Aron is cashing in 1.25 million of his 3.25 million shares of AMC stock. Here's why should should follow his example.

Ocugen Needs More Than Covaxin to Boost Its Falling Shares

By Chris Tyler, InvestorPlace Contributor
A doomed-looking vaccine partnership puts Ocugen back in the business of obscurity and OCGN stock at risk of much lower prices.

Take a Bearish Stance on Bruised and Battered Deciphera Pharmaceuticals

By David Moadel, InvestorPlace Contributor
Unfavorable clinical results and a wide earnings miss will undoubtedly sink DCPH stock. Resist the temptation to buy the dip.

With Progenity, What Is Pumped Will Be Dumped

By Dana Blankenhorn, InvestorPlace Contributor
Progenity came public as a genetic testing company in 2020, then closed the lab and is doing early-stage clinical trials.

Skillz Stock Has Too Much of Its Potential Already Priced In

By Faizan Farooque, InvestorPlace Contributor
SKLZ stock is a long-term investment, but the price already reflects the potential of the mobile esports platform before it is realized.
Load More Articles